DRAFT HPTN 035 Dissemination Plan

First Page		Document Content
Date: 2011-07-18 13:56:21 Microbiology Gilead Sciences Sexually transmitted diseases and infections HIV/AIDS Clinical research Pre-exposure prophylaxis IPrEx CAPRISA 004 Tenofovir/emtricitabine Medicine Health Microbicides		DRAFT HPTN 035 Dissemination Plan Add to Reading List Source URL: www.mtnstopshiv.org Download Document from Source Website File Size: 60,92 KB Share Document on Facebook

	An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis DocID: 1ut18 - View Document
	Pragmatic Open-Label Randomised Trial of Pre-Exposure Prophylaxis: the PROUD study http://www.proud.mrc.ac.uk/ DocID: 1uc90 - View Document
	A publication for men and transgender women who have sex with men Pre-exposure Prophylaxis Is taking PrEP the DocID: 1u249 - View Document
	Final Draft – 11 MayGuidelines for Expanding Combination Prevention and Treatment Options for Sex Workers: Oral Pre-Exposure Prophylaxis (PrEP) and Test and Treat (T&T) DocID: 1t04u - View Document
	Pre-Exposure Prophylaxis (PrEP): A primer for primary care providers Daily emtricitabine/tenofovir (Truvada®) is safe and effective for reducing the risk of HIV acquisition in sexually active men and women and injection DocID: 1rPaA - View Document